TECHBio-Techne Corp

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Charles R. Kummeth

Location

Minnesota, USA

Exchange

Nasdaq

Website

https://bio-techne.com

Summary

Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services.

Company Info

CEO

Charles R. Kummeth

Location

Minnesota, USA

Exchange

Nasdaq

Website

https://bio-techne.com

Summary

Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services.

AI Insights for TECH
5 min read

Quick Summary

Bio-Techne Corporation is a Minneapolis-based life sciences company that develops, manufactures, and sells reagents, instruments, diagnostics products, and related services. The company serves researchers, biopharmaceutical companies, clinical laboratories, diagnostics manufacturers, academic institutions, and cell and gene therapy developers. Its Protein Sciences segment supplies biological reagents and tools used in life science research, drug discovery, diagnostics development, and advanced therapy workflows. Its Diagnostics and Genomics segment provides controls, calibrators, diagnostic assays, and genomics-related products for regulated diagnostics and applied research markets. Bio-Techne’s products are typically used by customers who need high-quality proteins, antibodies, assays, sample analysis tools, and quality-control materials for scientific and clinical applications.

Strengths

•

Bio-Techne’s main strength is its specialized portfolio of high-value reagents, assays, diagnostic controls, and analytical tools used in important life science workflows.

•

The company benefits from strong gross profitability, with gross profit representing a large portion of revenue, which suggests pricing power and differentiated products.

•

It has exposure to attractive long-term markets, including biopharma research, immunology, oncology, molecular diagnostics, and cell and gene therapy.

•

Bio-Techne also benefits from recurring demand because researchers and clinical laboratories frequently reorder reagents, controls, consumables, and assay components.

•

Its established customer relationships, technical expertise, and broad catalog give it a competitive position in specialized life science tools.

Key Risks

•

The company faces valuation risk because the stock appears priced for sustained growth and strong execution.

•

If revenue growth slows, margins compress, or free cash flow disappoints, the share price could decline significantly.

•

Competitive risk is also meaningful because large companies such as Thermo Fisher, Danaher, Agilent, and Bio-Rad have broader distribution networks and substantial R&D budgets.

•

End-market risk includes weaker biotech funding, lower academic research budgets, delays in diagnostic adoption, and reduced capital spending by laboratories.

What to Watch

The most recent reported period shows Bio-Techne with total revenue of about $1.215 billion, gross profit of about $799.1 million, operating income of about $251.9 million, and net income of about $181.9 million.
The company remains profitable, with diluted EPS of $1.16 and basic EPS of $1.17.
Its gross profit base indicates that the business has attractive product economics, although valuation remains demanding relative to current earnings.
The provided data does not identify a specific new product launch, acquisition, or partnership during the quarter.
The reported fundamentals instead suggest that investors are likely focused on revenue durability, margin execution, diagnostics demand, and whether the company can justify its premium valuation.

Price Drivers

•

Bio-Techne’s stock price is primarily driven by revenue growth, operating margin performance, earnings quality, free cash flow generation, and investor expectations for life science research demand.

•

The company trades at a high valuation, with a price-to-earnings ratio above 60 and EV-to-EBITDA above 33, so even small disappointments in growth or margins can have an outsized impact on the share price.

•

Biopharma R&D spending, academic research funding, diagnostics demand, and cell and gene therapy activity are major end-market drivers.

•

Interest rates also matter because high-multiple life sciences stocks tend to be pressured when discount rates rise or investors rotate toward lower-valuation sectors.

•

Broader market sentiment toward growth stocks, healthcare tools companies, and profitable innovation-focused manufacturers can also influence TECH’s valuation.

Recent News

•

The provided recent news items are mostly about large technology and semiconductor companies such as Nvidia, Lam Research, Marvell, Apple, Alphabet, eBay, and Booking Holdings.

•

They do not appear to include company-specific news about Bio-Techne, such as a new acquisition, product launch, regulatory event, or strategic partnership.

•

As a result, there is no direct recent-news catalyst for TECH in the supplied news set.

•

The absence of company-specific headlines means investors may be relying more heavily on fundamentals, sector trends, earnings expectations, and valuation signals.

•

Indirectly, broader market discussion about high-growth technology and AI spending can influence investor risk appetite, but it is not directly tied to Bio-Techne’s life sciences business.

Market Trends

•

Bio-Techne is affected by broader trends in life science research, diagnostics, biotechnology funding, and healthcare innovation.

•

Long-term demand for biologics, cell therapy, gene therapy, immunology research, oncology tools, and molecular diagnostics supports the need for high-quality reagents and analytical platforms.

•

At the same time, life science tools companies can face pressure when biotech capital markets weaken or customers reduce inventories after periods of heavy purchasing.

•

Higher interest rates can weigh on premium-growth healthcare tools stocks because future earnings are discounted more heavily.

•

The market is also favoring companies that can demonstrate durable organic growth, recurring revenue, pricing power, and strong free cash flow conversion.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on TECH

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@ProduceCut309 9 months ago

Rotation Season Is Here. Are You Still Heavy in Tech

Rotation Season Is Here. Are You Still Heavy in Tech

Money’s starting to move out of big tech and into other corners of the market as Wall Street cools off on the AI hype trade. After monster runs in names like , , and , a lot of traders are locking in gains and hunting for better risk reward elsewhere. The rotation seems to be leaning toward stuff like , , and industrial names that actually benefit if growth slows but the economy doesn’t fall apart. It’s not that AI is dead, it’s more that expectations got stretched and valuations got crowded fast. Feels like the market’s asking a real question now. Do you stick with mega cap tech and ride the volatility, or rotate into cheaper sectors before leadership really shifts? What’s your move right now, staying heavy in or spreading bets elsewhere.

avatar
@ProduceCut309 9 months ago

Global Equities Back in Favor as Rate Cut Hopes Build

Global Equities Back in Favor as Rate Cut Hopes Build

Global equity funds just pulled in big money again, seeing their largest inflows in about five weeks as traders get more comfortable with the macro backdrop. Roughly $36 billion flowed into stock funds worldwide, showing investors are leaning back into equities after a run of AI-driven volatility. The shift looks tied to two big themes: cooling worries and renewed bets that cuts are still coming if inflation keeps losing steam. When both of those lines up, risk assets tend to benefit because cheap capital usually lifts stocks. Money wasn’t just piling into one region either. Europe and .S. equity funds both saw solid inflows, and Asian funds got a piece of the pie too. Sectors like , INDUSTRIALS, and METALS & MINING were among the biggest beneficiaries as portfolio managers repositioned into broader exposure. On the fixed income side, bond and money market funds are still getting action, while gold and precious metals saw some trimming as money rotated back into stocks. Overall, this flow picture tells you that traders aren’t throwing in the towel. Instead, they’re buying dips and leaning into the idea that easier policy and softer inflation data will keep markets supported. This isn’t a screaming breakout yet, but it’s a solid sign that confidence is slowly rebuilding in global equities across regions and sectors as the macro story evolves.

avatar
@CopyRemarkable14 9 months ago

Ali Partovi’s Neo Takes Aim at Traditional Accelerators

Ali Partovi’s Neo Takes Aim at Traditional Accelerators

Ali Partovi’s Neo is trying to flip the accelerator game on its head. Instead of the usual heavy dilution, Neo is backing early founders with low-equity, founder-friendly terms that let them keep more upside if things work out. The big idea is simple: give capital and mentorship without taxing ownership early. That’s a sharp contrast to the traditional accelerator model that locks in fixed equity before a startup even finds product-market fit. If this catches on, it could shift how early-stage funding works across and $STARTUPS, especially as founders get more selective about who they partner with. Not a threat to the big names yet, but definitely pressure on the old playbook. More leverage for founders, less dilution upfront, and more competition in the space.

avatar
@ProduceCut309 9 months ago

AI Reality Check Hits Wall Street

AI Reality Check Hits Wall Street

Wall Street is finally talking about the dark side of AI. After a huge run, a lot of and $software stocks are getting smacked as traders start worrying about disruption instead of just hype. Earnings misses, stretched valuations, and fears that AI could eat into existing businesses are all hitting sentiment. This selloff isn’t random. When a trade gets crowded like AI did, the market stops chasing stories and starts asking one thing. Where are the real profits? That’s why former leaders are getting chopped and volatility is creeping back in. Feels more like a reset than a full breakdown. AI isn’t dead, but the easy money phase is over. Now it’s about who can actually turn AI into cash flow instead of buzzwords. Big question now is whether this is just a breather or the start of a deeper tech shakeout. Markets about to decide. 

No more topics to show